---
document_datetime: 2024-02-23 13:44:46
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ryeqo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ryeqo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.6730339
conversion_datetime: 2025-12-23 03:02:58.827672
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ryeqo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0022              | B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms | 18/01/2024                          |                                             | SmPC, Labelling and PL           |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/10942 /202305   | Periodic Safety Update EU Single assessment - relugolix / estradiol / norethisterone acetate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/01/2024   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| IB/0023               | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 05/01/2024   | n/a   |                                     |
| II/0020/G             | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 07/12/2023   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                            |            |            |             |                                                                    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------|
| II/0019/G | This was an application for a group of variations. B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition) B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a | 07/12/2023 | n/a        |             |                                                                    |
| II/0013/G | This was an application for a group of variations. Extension of indication to include symptomatic treatment of endometriosis for RYEQO in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis, based on final results from studies MVT-601-3101                                                                                                                                                                                                                                                                                                                                                                 | 14/09/2023 | 30/10/2023 | SmPC and PL | Please refer to Scientific Discussion 'Ryeqo-H-C-005267-II- 0013-G |

<div style=\"page-break-after: always\"></div>

| and MVT-601-3102 and from study MVT-601-3103. are pivotal, phase III, randomised, placebo-controlled, safety evaluate relugolix with combination therapy for endometriosis. Study 3103 extension study including one of the two pivotal studies criteria, regardless of their the pivotal studies. In the received relugolix combination consequence, sections the SmPC were updated. updated in accordance. Update of section 4.5 of information regarding Drug-Drug on final results of DDI studies 601-55 and MVT-601-57. part interventional open-label potential effects of erythromycin components of Ryeqo. interventional open label over study to assess whether separation is sufficient mediated increased exposure MVT-601-057 is a 2-part potential effect of relugolix dabigatran. The updated RMP version submitted. As part of the   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | one additional year. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                      |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0017/G           | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                           | 18/08/2023 | n/a |                                   |
| PSUSA/10942 /202211 | Periodic Safety Update EU Single assessment - relugolix / estradiol / norethisterone acetate                                                                                                                                                                                                                                                                                                                                               | 06/07/2023 | n/a | PRAC Recommendation - maintenance |
| IB/0016/G           | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 24/05/2023 | n/a |                                   |
| IA/0018             | B.II.d.2.a - Change in test procedure for the finished                                                                                                                                                                                                                                                                                                                                                                                     | 23/05/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10942 /202205 | Periodic Safety Update EU Single assessment - relugolix / estradiol / norethisterone acetate                                                                                                                                                                                                                                                                                                      | 26/01/2023 | 31/03/2023 | SmPC and PL | Scientific conclusions and grounds for variation to the terms of the marketing authorisations In view of available data on urticaria and angioedema from clinical trials and spontaneous reports including cases with close temporal relationship, a positive de-challenge and/or re-challenge, and in view of a plausible mechanism of action, the PRAC considers a causal relationship between the combination relugolix/estradiol/norethisterone acetate and urticaria and angioedema is at least a reasonable possibility. The PRAC concluded that the product information of medicinal products containing the combination relugolix/estradiol/norethisterone acetate should be amended accordingly. |
| II/0012             | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                                                               | 23/02/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0009             | Update of sections 5.3 and 6.6 of the SmPC based on final results from MVT-601- 9030_Relugolix_ZEOGRT_Study (Rec); this is a fish, full life cycle test performed in the context of the Environmental Risk Assessment of relugolix. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 30/06/2022 | 31/03/2023 | SmPC and PL | Please refer to Scientific Discussion 'Ryeqo-H-C-5267-II- 09'.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IB/0010             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                      | 20/06/2022   | 22/07/2022   | SmPC            |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|-----------------------------------|
| PSUSA/10942 /202111 | Periodic Safety Update EU Single assessment - relugolix / estradiol / norethisterone acetate                                                                                   | 10/06/2022   | n/a          |                 | PRAC Recommendation - maintenance |
| IB/0008             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data         | 11/05/2022   | n/a          |                 |                                   |
| II/0006             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                  | 05/05/2022   | n/a          |                 |                                   |
| IB/0005             | B.I.b.z - Change in control of the AS - Other variation                                                                                                                        | 22/12/2021   | n/a          |                 |                                   |
| IA/0004/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites | 11/10/2021   | 22/07/2022   | Annex II and PL |                                   |
| IB/0002/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation        | 02/09/2021   | n/a          |                 |                                   |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                        |            |            |                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0001   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                         | 27/08/2021 | 22/07/2022 | SmPC, Labelling and PL |
| IA/0003/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 05/08/2021 | n/a        |                        |